Active	Status	Sponsor type	Region	Phase	Filter
5 Active 2 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Solomon, Richard J
NCT01456013: Evaluation of RenalGuard® System to Reduce the Incidence of Contrast Induced Nephropathy in At-Risk Patients	Active, not recruiting	3	326	US	RenalGuard Therapy, Standard Therapy	CardioRenal Systems, Inc.	Contrast Induced Nephropathy	03/18	12/24
EAGLE, NCT03749447 / 2018-003253-24: An Extended Access Program for Bardoxolone Methyl in Patients With CKD	Terminated	3	270	Europe, Japan, US, RoW	Bardoxolone methyl, RTA 402	Reata, a wholly owned subsidiary of Biogen, Reata Pharmaceuticals, Inc.	Chronic Kidney Diseases, Alport Syndrome, Autosomal Dominant Polycystic Kidney	08/23	08/23
FALCON, NCT03918447 / 2018-004651-20: A Trial of Bardoxolone Methyl in Patients With ADPKD -	Terminated	3	667	Europe, Japan, US, RoW	Bardoxolone methyl oral capsule, RTA 402, Placebo oral capsule	Reata, a wholly owned subsidiary of Biogen, Reata Pharmaceuticals, Inc., REATA PHARMACEUTICALS, INC	Autosomal Dominant Polycystic Kidney, ADPKD	08/23	08/23
NCT04939116 / 2021-006579-41: Study of Safety and Efficacy of ANG-3070 in Chronic Kidney Disease	Recruiting	2	100	US, RoW	ANG-3070, Placebo	Angion Biomedica Corp, Angion Biomedica Corp.	Glomerular Disease, Proteinuria	07/23	08/23
NCT05514548 / 2022-002140-51: Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease	Completed	2	265	Europe, Canada, US, RoW	INV-202, None applicable, Placebo	Inversago Pharma Inc., Worldwide Clinical Trials	Diabetic Kidney Disease	08/24	09/24